Agenus Inc. (AGEN)
2.55
-0.30 (-10.53%)
At close: Mar 03, 2025, 3:59 PM
2.53
-0.78%
After-hours: Mar 03, 2025, 05:04 PM EST
No 1D chart data available
| Bid | 2.51 |
| Market Cap | 59.82M |
| Revenue (ttm) | 174.64M |
| Net Income (ttm) | -247.81M |
| EPS (ttm) | -11.02 |
| PE Ratio (ttm) | -0.23 |
| Forward PE | -0.49 |
| Analyst | Hold |
| Ask | 2.54 |
| Volume | 373,255 |
| Avg. Volume (20D) | 417,956 |
| Open | 2.89 |
| Previous Close | 2.85 |
| Day's Range | 2.53 - 2.83 |
| 52-Week Range | 2.50 - 19.69 |
| Beta | 1.30 |
About AGEN
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 8, 2000
Employees 389
Stock Exchange NASDAQ
Ticker Symbol AGEN
Website https://www.agenusbio.com
Analyst Forecast
According to 3 analyst ratings, the average rating for AGEN stock is "Hold." The 12-month stock price forecast is $10.5, which is an increase of 311.76% from the latest price.
Buy 33.33%
Hold 66.67%
Sell 0.00%
Next Earnings Release
Agenus Inc. is scheduled to release its earnings on Mar 11, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
7 months ago
-58.83%
Agenus shares are trading lower after the company ...
Unlock content with
Pro Subscription
10 months ago
-8.12%
Agenus shares are trading lower. The company announced updated results from its Phase 1 clinical trial of BOT/BAL combination therapy in patients with metastatic CRC that is not microsatellite instability-high or deficient mismatch repair.
